GC
CYTK icon

Globeflex Capital’s Cytokinetics CYTK Stock Holding History

Globeflex Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-139,065
Closed -$1.69M – 484
2016
Q4 		$1.69M Buy
+139,065
New +$1.48M 0.42% 51
2016
Q3 		– Sell
-83
Closed -$1K – 495
2016
Q2 		$1K Hold
83
– – ﹤0.01% 387
2016
Q1 		$1K Hold
83
– – ﹤0.01% 381
2015
Q4 		$1K Hold
83
– – ﹤0.01% 368
2015
Q3 		$1K Hold
83
– – ﹤0.01% 429
2015
Q2 		$1K Sell
83
-59
-42% -$387 ﹤0.01% 430
2015
Q1 		$1K Sell
142
-237
-63% -$1.77K ﹤0.01% 431
2014
Q4 		$3K Buy
379
+174
+85% +$747 ﹤0.01% 394
2014
Q3 		$1K Buy
+205
New +$861 ﹤0.01% 450

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Globeflex Capital's CYTK Position: Q1 2017 in Review

Globeflex Capital sold out of Cytokinetics (CYTK) in Q1 2017, closing a stake of 139,065 shares — an estimated $1.69M sold.

Globeflex Capital first reported a position in CYTK in Q3 2014 and held it in 9 quarters. The position peaked at $1.69M in Q4 2016. 108 funds tracked by Wall St. Rank hold CYTK as of Q1 2017.

  • Globeflex Capital reported no remaining Cytokinetics position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 139,065 Cytokinetics shares in Q1 2017, an estimated $1.69M.
  • Globeflex Capital first reported a position in Cytokinetics in Q3 2014 and held it in 9 quarters.
  • Globeflex Capital's Cytokinetics position peaked at $1.69M in Q4 2016.
  • 108 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.